Edesa Biotech is trading 5.69% up now at $5.57, continuing positive biotech-sector sentiment linked to argenx’s $2.2 billion acquisition of Forte Biosciences.
- The transaction includes a $77-per-share tender offer.
- It has encouraged speculation about strategic value across clinical-stage biotech companies, including those with immunology or vitiligo programs.
- No new company-specific announcement for August 10, 2026 was identified.